FDCDDQ
SABS icon

Federation des caisses Desjardins du Quebec’s SAB Biotherapeutics SABS Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-250
Closed -$949 – 2743
2024
Q4 		$949 Buy
+250
New +$821 ﹤0.01% 2327

Other funds holding SABS

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $15.5B AUM 18.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOS
Silver Oak Securities Jackson, Tennessee $1.37B AUM 20.67% 1-Year Est. Return
Kovitz Investment Group Partners
Kovitz Investment Group Partners Chicago, Illinois $4.31B AUM 20.41% 1-Year Est. Return
FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's SABS Position: Q1 2025 in Review

Federation des caisses Desjardins du Quebec sold out of SAB Biotherapeutics (SABS) in Q1 2025, closing a stake of 250 shares — an estimated $949 sold.

Federation des caisses Desjardins du Quebec first reported a position in SABS in Q4 2024 and held it in 1 quarter. The position peaked at $949 in Q4 2024. 26 funds tracked by Wall St. Rank hold SABS as of Q1 2025.

  • Federation des caisses Desjardins du Quebec reported no remaining SAB Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Federation des caisses Desjardins du Quebec sold 250 SAB Biotherapeutics shares in Q1 2025, an estimated $949.
  • Federation des caisses Desjardins du Quebec first reported a position in SAB Biotherapeutics in Q4 2024 and held it in 1 quarter.
  • Federation des caisses Desjardins du Quebec's SAB Biotherapeutics position peaked at $949 in Q4 2024.
  • 26 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2025.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2025, filed 15 May 2025.